Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	80875
Country	China

Received	2022-10-15 14:39
Peer-Review Started	2022-10-15 14:42
To Make the First Decision
Return for Revision	2022-11-02 14:09
Revised	2022-11-11 11:48
Second Decision	2023-03-13 03:05
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-03-16 05:41
Articles in Press	2023-03-16 05:41
Publication Fee Transferred
Edit the Manuscript by Language Editor	2023-03-07 03:20
Typeset the Manuscript	2023-04-06 04:40
Publish the Manuscript Online	2023-04-12 08:10

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Recent advances in targeted therapy for pancreatic adenocarcinoma
Manuscript Source	Invited Manuscript
All Author List	Yu-Ting Fang, Wen-Wei Yang, Ya-Ru Niu and Yong-Kun Sun
Funding Agency and Grant Number	Funding Agency Grant Number National Key Research and Development Program of China 2021YFF1201300 The Special Foundation of Wu Jieping Medical Foundation for Clinical Scientific Research 320.6750.2022-10-95
Corresponding Author	Yong-Kun Sun, MD, Professor, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Pan-jia-yuan South Lane, Chaoyang District, Beijing 100021, China. hsunyk@cicams.ac.cn
Key Words	Pancreatic carcinoma; Targeted therapy; Cancer stem cell; Monoclonal antibody; Epigenetic modifier
Core Tip	Pancreatic adenocarcinoma (PDAC) is a fatal and rare disease with a 5-year survival rate of 8% and a median survival of 6 mo. In PDAC, targeted therapy has been extensively evaluated; however, survival improvement of this aggressive disease using a targeted strategy has been minimal. This manuscript summarizes current targeted therapies and clinical trials targeting dysregulated signaling pathways and components of the PDAC oncogenic process, analyzes possible reasons for the lack of positive results in clinical trials, and suggests ways to improve them. We also discuss emerging trends in targeted therapies for PDAC: combining targeted inhibitors of multiple pathways.
Publish Date	2023-04-12 08:10
Citation	Fang YT, Yang WW, Niu YR, Sun YK. Recent advances in targeted therapy for pancreatic adenocarcinoma. World J Gastrointest Oncol 2023;15(4): 571-595
URL	https://www.wjgnet.com/1948-5204/full/v15/i4/571.htm
DOI	https://dx.doi.org/10.4251/wjgo.v15.i4.571

Full Article (PDF)	WJGO-15-571.pdf
Full Article (Word)	WJGO-15-571.docx
Manuscript File	80875_Auto_Edited-LM.docx
Answering Reviewers	80875-Answering reviewers.pdf
Audio Core Tip	80875-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	80875-Conflict-of-interest statement.pdf
Copyright License Agreement	80875-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	80875-Grant application form(s).pdf
Non-Native Speakers of English Editing Certificate	80875-Language certificate.pdf
Peer-review Report	80875-Peer-review(s).pdf
Scientific Editor Work List	80875-Scientific editor work list.pdf